Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denifanstat and Resmetirom DDI Study in Healthy Adults
NCT07216313Phase 1Completed
- Sponsor
- Sagimet Biosciences
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH) (2 cohorts), sponsored by Sagimet Biosciences. Primary endpoints: Area under the concentration-time curve during a dosing interval at steady state at 7 days and Maximum observed concentration at steady-state at 7 days. Started Sep 2025; status: completed.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07216313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216313.